Clinical Trial Update: Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of Tetra-O-Methyl Nordihydroguaiaretic Acid for recurrent high-grade glioma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors

Drugs mentioned

• Tetra-O-Methyl Nordihydroguaiaretic Acid (Tetra-O-Methyl Nordihydroguaiaretic Acid)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-08-11